Economic Evaluation of Expanding HPV Vaccination Programs for Boys: A Systematic Review

Ditya Tiwi Syafira; Dwi Endarti; Marteen J. Postma

doi:10.30595/jhepr.v2i2.157

Authors

Ditya Tiwi Syafira Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
Dwi Endarti Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
Marteen J. Postma University Medical Center Groningen, Groningen, The Netherlands

DOI:

https://doi.org/10.30595/jhepr.v2i2.157

Keywords:

Cost-effectiveness, Human Papillomavirus, Vaccination, Boys

Abstract

Background: Human papillomavirus is responsible for almost all cases of cervical and non-cervical cancers. Various treatments have been carried out, but they have not been effective enough in reducing the burden. The U.S. Food and Drug Administration has approved three HPV vaccines for use. Since its recommendation in 2006, HPV infections have significantly decreased by 88% among teen girls and 81% among young adult women. Additionally, research has indicated that HPV vaccine is cost-effective in preventing both cervical and non-cervical cancers. The primary target group of HPV vaccination is girls aged 9-14, but some countries are starting to expand their programs according to the WHO recommendation for secondary targets: boys and adult women. This study gave updated information regarding the expansion of HPV vaccination programs for boys. Objective: To systematically review the health economic studies to evaluate the cost-effectiveness of expanding HPV vaccination program for including boys to prevent HPV-related cancer. Method: An electronic literature search was performed on two databases (Pubmed and ScienceDirect) to identify studies published from 2013 to 2023 in English and Indonesian. Three search strategies were used, including the terms «economic evaluation», «HPV», and «boys». The screening and selection of the literature was performed according to the PRISMA statement. Results: A total of 306 articles were identified. Only 26 of them were deemed relevant. This research compiled studies from countries with varying economic levels on the expansion of vaccination programs in boys to prevent or reduce cervical, anogenital, and HNC cancers. All the studies used a modeling approach to estimate the number of cases averted and the health care costs. Sixteen studies found that it was cost-effective to expand HPV vaccination programs to include boys. The ICER values were found to be sensitive to the vaccine price, duration of protection, and vaccination coverage. Conclusion: Expanding HPV vaccination to boys is considered a cost-effective solution for preventing HPV-related cancers, based on studies conducted in many countries. It is recommended to conduct an economic evaluation to estimate the cost-effectiveness of HPV vaccination as a prevention method for HPV-related cancers in low and middle-income countries like Indonesia. To begin the study, it is suggested to expand the HPV vaccination target to boys with a lower-priced vaccine and increased vaccination coverage.

References

WHO. Human Papillomavirus (HPV)(2023).

Prigge, E. S., Von Knebel Doeberitz, M. & Reuschenbach, M. Clinical relevance and implications of HPV-induced neoplasia in different anatomical locations. Mutat. Res. Mutat. Res. 772, 51–66 (2017).

National Cancer Institute. HPV and Cancer.

Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 71, 209–249 (2021).

Chen, S. et al. Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050. JAMA Oncol. 9, 465 (2023).

American Cancer Society. The Economic Burden of Cancer. The Cancer Atlas (2019).

Jemal, A. et al. Global cancer statistics. CA. Cancer J. Clin. 61, 69–90 (2011).

Demarteau, N., Tang, C.-H., Chen, H.-C., Chen, C.-J. & Van Kriekinge, G. Cost-Effectiveness Analysis of the Bivalent Compared with the Quadrivalent Human Papillomavirus Vaccines in Taiwan. Value Health 15, 622–631 (2012).

CDC. Human Papillomavirus(2021).

Ding, W. et al. The lifetime cost estimation of human papillomavirus-related diseases in China: a modeling study. J. Transl. Intern. Med. 9, 200–211 (2021).

De Kok, I. M. C. M., Habbema, J. D. F., Van Rosmalen, J. & Van Ballegooijen, M. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? Eur. J. Cancer 47, 428–435 (2011).

Chanthavilay, P. et al. The economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach. BMC Health Serv. Res. 16, 418 (2016).

Kitano, T. Risk-Benefit Analysis of the 9-Valent HPV Vaccination for Adolescent Boys from an Individual Perspective. Jpn. J. Infect. Dis. 75, 114–120 (2022).

Cheung, T. H. et al. Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong. Hum. Vaccines Immunother. 19, 2184605 (2023).

Wahab, M. T., Tan, R. K. J., Cook, A. R. & Prem, K. Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis. Vaccine 41, 1934–1942 (2023).

Laprise, J.-F. et al. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. Vaccine 32, 5845–5853 (2014).

Brisson, M. et al. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. J. Natl. Cancer Inst. 108, djv282 (2016).

Graham, D. M. et al. A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer: Male HPV Vaccination for OPC Prevention. Cancer 121, 1785–1792 (2015).

Chesson, H. W., Meites, E., Ekwueme, D. U., Saraiya, M. & Markowitz, L. E. Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States. Vaccine 36, 4362–4368 (2018).

Chesson, H. W., Meites, E., Ekwueme, D. U., Saraiya, M. & Markowitz, L. E. Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model. Vaccine 38, 8032–8039 (2020).

Choi, S. E. et al. Increasing HPV vaccination coverage to prevent oropharyngeal cancer: A cost-effectiveness analysis. Tumour Virus Res. 13, 200234 (2022).

Wolff, E. et al. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. Vaccine 36, 5160–5165 (2018).

Burger, E. A., Sy, S., Nygård, M., Kristiansen, I. S. & Kim, J. J. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PloS One 9, e89974 (2014).

Jimenez, J. E. et al. Surgical factors associated with patient-reported quality of life outcomes after free flap reconstruction of the oral cavity. Oral Oncol. 123, 105574 (2021).

Boiron, L., Joura, E., Largeron, N., Prager, B. & Uhart, M. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infect. Dis. 16, 153 (2016).

Mennini, F. S. et al. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost Eff. Resour. Alloc. CE 15, 11 (2017).

Qendri, V., Bogaards, J. A. & Berkhof, J. Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands. J. Infect. Dis. 216, 210–219 (2017).

Datta, S. et al. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK. BMC Infect. Dis. 19, 552 (2019).

Qendri, V. et al. The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment. Lancet Public Health 5, e592–e603 (2020).

Simons, J. J. M., Vida, N., Westra, T. A. & Postma, M. J. Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands. Vaccine 38, 4687–4694 (2020).

Majed, L. et al. Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France. Vaccine 39, 438–446 (2021).

Portnoy, A. et al. Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis. Prev. Med. 144, 106276 (2021).

Daniels, V. et al. Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom. Vaccine 40, 2173–2183 (2022).

Linertová, R., Guirado-Fuentes, C., Mar-Medina, J. & Teljeur, C. Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain. Hum. Vaccines Immunother. 18, 2127983 (2022).

Blakely, T. et al. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. Vaccine 32, 2645–2656 (2014).

Pearson, A. L. et al. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program. BMC Infect. Dis. 14, 351 (2014).

Drolet, M. et al. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. Lancet Infect. Dis. 21, 1598–1610 (2021).